Wegovy annual sales: how the numbers behind semaglutide add up

How large have Wegovy's global annual sales actually become?

Novo Nordisk's semaglutide products (primarily Wegovy for weight management and Ozempic for type 2 diabetes) generated combined revenues that placed the company briefly among the most valuable in Europe by market capitalisation in 2024. Wegovy's weight-management revenues specifically have grown from a standing start at US launch in 2021 to billions of dollars annually within a few years, with the UK and European rollout adding momentum from 2023 onwards.

Reported figures vary by quarter and by how Novo Nordisk segments weight-care versus diabetes revenues in its financial disclosures. For readers trying to make sense of these numbers, the honest framing is this: semaglutide has become a blockbuster medicine by any measure used in the pharmaceutical industry. Anyone tracking the broader commercial picture may find it useful to look at how semaglutide sales have developed across markets, and for context on how 2024 and 2025 figures broke down, the semaglutide sales picture for 2024 sets out the annual trajectory in detail.

What matters clinically is that demand at this scale has shone a light on supply chains, counterfeiting risk and the quality of services patients use to access treatment. A medicine with this commercial profile attracts both reputable providers and, as the MHRA has warned publicly, illegitimate ones selling without a valid prescription and outside the licensed supply chain.

What is driving the sales growth, and does it reflect clinical evidence?

The short answer is yes. The commercial trajectory of Wegovy tracks closely with a body of clinical trial evidence that genuinely impressed regulators. The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks and recorded an average weight reduction of around 15% at the 2.4mg maintenance dose, a figure substantially larger than earlier licensed weight-loss medicines had achieved. NICE reviewed this evidence and recommended semaglutide for weight management in 2023 under technology appraisal TA875, albeit within specialist weight management services and for a maximum of two years.

The April 2026 approval of a dedicated single-dose 7.2mg Wegovy pen by the MHRA added a higher maintenance option for adults with a BMI of 30 or above, with trials at this dose reporting average weight loss of around 20.7% over 72 weeks. That approval broadened the medicine's clinical toolkit and is likely to sustain demand further, with analysts already debating what Wegovy sales in 2025 will look like once full-year data are published. For a fuller picture of what Wegovy costs through a private regulated service, the Wegovy cost guide covers what to expect and why headlines figures can be misleading.

The sales numbers, in other words, are not driven by clever marketing alone. They reflect a medicine that has changed prescribing confidence around obesity treatment.

Does the UK experience mirror the global sales picture?

Not exactly. The UK rollout has been more constrained than the United States, where direct-to-consumer advertising and broader insurance coverage accelerated uptake sharply. In the UK, Wegovy is prescription-only and the NHS route is restricted to specialist weight management services with defined eligibility criteria. Waiting lists on the NHS remain long in many areas, which has pushed a significant number of patients toward private regulated services.

Private availability through GPhC-registered online pharmacies has grown considerably. Many people who fall outside current NHS thresholds (or who simply cannot wait) access treatment this way, legally and safely, after a clinical assessment. That private demand contributes to UK sales volumes, even if it is never reflected in NHS prescribing statistics. Patients sometimes search for a Wegovy sale or promotional price before committing, and while occasional discounts do exist through legitimate providers, it is worth understanding what any reduced price actually includes in terms of clinical support.

It is also worth noting that the strong sales figures have had an unintended consequence: they have made Wegovy a target for counterfeit supply. The MHRA has issued repeated warnings about fake weight-loss pens sold via social media and unregistered online sources. Checking any online pharmacy against the GPhC register before placing an order is the simplest way to confirm it operates lawfully. You can also report any suspect seller directly through the MHRA's Yellow Card scheme.

What do the sales figures mean for someone considering treatment?

Practically speaking, very little, and that is worth saying plainly. The size of Wegovy's commercial success does not change whether it is clinically suitable for you. A prescriber still needs to assess your health history, BMI, current medicines and any conditions that might affect how you respond to semaglutide. The medicine is not available over the counter, and a large annual sales figure does not make it safer to obtain it any other way.

What the growth does signal is that treatment pathways are maturing. Supply has gradually caught up with demand for most dose strengths, clinician familiarity with the medicine has grown, and aftercare standards at regulated services have improved as the market has developed. Reviewing how Wegovy sales have evolved over time gives a sense of just how quickly those pathways have had to scale. If you are exploring whether Wegovy or another licensed weight-management medicine suits your situation, the weight-loss treatment overview covers the options available through a UK-regulated private service, and our clinical team reviews every consultation personally. Before the school run or after it, speak to our prescribers when it suits you.